SOPH SOPHiA GENETICS SA
Price Chart
Executive Summary
SOPHiA GENETICS filed its 2026 Annual General Meeting proxy materials, including a CEO succession plan where founder Dr. Jurgi Camblong transitions to Executive Chair and President Ross Muken becomes CEO effective July 1, 2026. The filing also includes FY2025 financial results: revenue of $77.3M (up 19% YoY), IFRS net loss of $79.0M (vs $62.5M loss in FY2024), and adjusted EBITDA loss of $41.5M (vs $40.2M loss in FY2024). The company expects to approach adjusted EBITDA breakeven by end of 2026 and turn positive in H2 2027.
Actionable Insight
The CEO transition is orderly and expected, with the founder remaining as Executive Chair — no disruption risk. The financials show revenue acceleration and margin improvement, but losses continue to widen. The adjusted EBITDA breakeven timeline (end of 2026) is the key catalyst to watch. Monitor Q1 2026 results for signs of operating leverage and whether the 115% net dollar retention sustains.
Key Facts
- FY2025 IFRS revenue of $77,271,000, up 19% from $65,173,000 in FY2024
- FY2025 IFRS net loss of $78,999,000, widened from $62,493,000 loss in FY2024
- FY2025 adjusted EBITDA loss of $41,500,000, slightly wider than $40,178,000 loss in FY2024
- FY2025 adjusted gross margin of 74.2%, up 140 bps from 72.8% in FY2024
- CEO transition: Founder Jurgi Camblong to Executive Chair, President Ross Muken to CEO effective July 1, 2026
- Company expects to approach adjusted EBITDA breakeven by end of 2026 and cross to positive in H2 2027
- Record 124 new customers added in FY2025, average contract value up 120% YoY
- Net dollar retention increased to 115% in FY2025 from 104% in FY2024
- Proposed conditional share capital increase to CHF 1,240,378.20 (up to 24,807,564 shares) for employee equity plan replenishment
Financial Impact
Revenue grew 19% YoY to $77.3M, but net loss widened 26% to $79.0M. Adjusted EBITDA loss remained roughly flat at $41.5M. Adjusted gross margin improved 140 bps to 74.2%.
Risk Factors
- Continued operating losses and cash burn — company not yet profitable
- Adjusted EBITDA breakeven target of end of 2026 may slip if revenue growth decelerates
- Potential dilution from annual conditional share capital increase (up to 5% of outstanding shares)
- Litigation expenses from Guardant Health lawsuits ($2.4M in FY2025)
Market Snapshot
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001840706-26-000178 |
| Document: agm2026sophiageneticssa6-k.htm | 0001840706-26-000178 |
| Document: a04afld_sophiaxgeneticsx.htm | 0001840706-26-000178 |
| Document: a04afjd_sophiaxgeneticsx.htm | 0001840706-26-000178 |
| Document: a04afkd_sophiaxgeneticsx.htm | 0001840706-26-000178 |
| Document: 0001840706-26-000178-index-headers.html | 0001840706-26-000178 |
| Document: 0001840706-26-000178-index.html | 0001840706-26-000178 |
| Document: 0001840706-26-000178.txt | 0001840706-26-000178 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 4, 2026
9d ago
|
6-K
| $4.96 $5.00 | ▲ +0.81% | ▲ +3.40% | $4.88 (−1.61%) |
|
Jun 1, 2026
12d ago
|
Insider Cluster
| $4.99 $4.94 | ▼ −1.00% | ▼ −1.15% | $4.88 (−2.20%) |
|
May 20, 2026
23d ago
|
Insider Cluster
| $5.05 $4.88 | ▼ −3.37% | ▼ −3.81% | $4.88 (−3.37%) |
|
May 19, 2026
25d ago
|
6-K
| $4.68 $4.87 | ▲ +4.06% | ▲ +3.02% | $4.88 (+4.27%) |
|
May 8, 2026
5w ago
|
6-K
| $5.15 $4.79 | ▼ −6.99% | ▼ −7.22% | $4.88 (−5.24%) |
|
May 5, 2026
5w ago
|
6-K
| $5.07 $5.02 | ▼ −0.99% | ▼ −2.37% | $4.88 (−3.75%) |
|
Apr 14, 2026
8w ago
|
Insider Cluster
| $4.96 $5.07 | ▼ −2.22% | ▼ −1.44% | $4.88 (+1.61%) |
|
Apr 8, 2026
9w ago
|
144
| $4.73 $4.70 | ▼ −0.63% | ▼ −0.57% | $4.88 (+3.17%) |
|
Apr 7, 2026
9w ago
|
Insider Cluster
| $4.90 $4.86 | ▼ −0.82% | ▼ −3.36% | $4.88 (−0.41%) |
|
Apr 6, 2026
9w ago
|
Insider Cluster
| $4.95 $4.90 | ▲ +1.01% | ▲ +1.07% | $4.88 (+1.41%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access